Kaitlin Kestenberg's most recent trade in Adma Biologics Inc was a trade of 18,920 Common Stock done at an average price of $19.4 . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.42 per share. | 01 Apr 2025 | 18,920 | 490,425 (0%) | 0% | 19.4 | 367,426 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.91 per share. | 06 Mar 2025 | 8,881 | 513,280 (0%) | 0% | 16.9 | 150,178 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.02 per share. | 06 Mar 2025 | 3,935 | 509,345 (0%) | 0% | 17.0 | 66,974 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.44 per share. | 25 Feb 2025 | 1,855 | 522,161 (0%) | 0% | 15.4 | 28,641 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 116,279 | 116,279 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 77,784 | 524,016 (0%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.80 per share. | 30 Jan 2025 | 5,000 | 449,587 (0%) | 0% | 10.8 | 54,000 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 5,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.10 per share. | 30 Jan 2025 | 3,355 | 446,232 (0%) | 0% | 16.1 | 54,016 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.15 per share. | 31 Dec 2024 | 1,854 | 444,587 (0%) | 0% | 17.1 | 31,796 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.99 per share. | 30 Sep 2024 | 2,647 | 446,441 (0%) | 0% | 20.0 | 52,914 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Sale of securities on an exchange or to another person at price $ 16.90 per share. | 30 Aug 2024 | 24,150 | 449,088 (0%) | 0% | 16.9 | 408,050 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 8,125 | 3,750 | - | - | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 30 Aug 2024 | 8,125 | 457,213 (0%) | 0% | 2.4 | 19,094 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 6,650 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.94 per share. | 30 Aug 2024 | 6,650 | 468,238 (0%) | 0% | 5.9 | 39,501 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 5,000 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share. | 30 Aug 2024 | 5,000 | 473,238 (0%) | 0% | 4.7 | 23,600 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 4,375 | 0 | - | - | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.59 per share. | 30 Aug 2024 | 4,375 | 461,588 (0%) | 0% | 2.6 | 11,331 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.58 per share. | 24 Jul 2024 | 2,502 | 449,088 (0%) | 0% | 13.6 | 33,977 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.18 per share. | 30 Jun 2024 | 2,085 | 451,590 (0%) | 0% | 11.2 | 23,310 | Common Stock |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 300,328 | 300,328 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 192,320 | 304,510 (0%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | Kaitlin Kestenberg | COO and SVP, Compliance | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.60 per share. | 31 Mar 2024 | 2,085 | 112,190 (0%) | 0% | 6.6 | 13,761 | Common Stock |